Loading, please wait...
This CE will provide pharmacists with knowledge on ensuring optimal medication therapy outcomes and patient safety for obese patients requiring anticoagulation for venous thromboembolism or atrial fibrillation; Satisfying educational requirements for pharmacist re-licensure
Fee
$10.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
Shenandoah University Bernard J. Dunn School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
To receive credit the following items must be completed
1. Register for the event through supharmacy.learningexpressce.com
2. Attend the entire activity
3. Complete all relevant learning assessments
4. Complete an activity evaluation through supharmacy.learningexpressce.com
Support/Credits
No external funding has been obtained for this activity. The speakers have no conflicts of interest to disclose.
Objectives
- Review the literature for the use of direct oral anticoagulants (DOACs) in obese patients with venous thromboembolism (VTE) and atrial fibrillation (AF)
- Recommend appropriate agents for the treatment of VTE and stroke prophylaxis in AF for obese patients
- Identify current guideline recommendations and updates
- Distinguish inappropriate use of anti-FXa monitoring
Speaker(s)/Author(s)
|
Matthew Brooks
Brief Bio : Matthew Brooks, PharmD, MS is a PGY1 pharmacy practice resident at Winchester Medical Center in Winchester, VA. Dr. Brooks completed his Doctor of Pharmacy degree at West Virginia University in 2021. His professional interests include hospital pharmacy and internal medicine. In his spare time, Dr. Brooks enjoys spending time with his fiancé, family, and friends, as well as exploring the surrounding areas and doing all things outdoors! |
Activity Number
0101-0000-22-005-H01-P
Release Date:
Jun 1, 2022
Credit Expiration Date:
Jun 1, 2025
CE Hours
1.00